To date, no clinically relevant safety issues have been reported other than transient injection site reactions (49%) and ...
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback